Clinical Trial Update: Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

View source ↗

Summary

Completed clinical trial analyzing cell count, viability, and immunogenicity of discarded newly diagnosed glioblastoma tissue or solid tumor tissues.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Snippet

Sponsor: Thomas Jefferson University | Conditions: Glioblastoma, Malignant Solid Neoplasm | Status: COMPLETED